Search

Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

• News
• Retinitis pigmentosa

The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.

• News

In August 2025, 8-year-old Rose Earnshaw is taking on a challenge like no other – completing 5 laps of her local village park (1 mile) every day throughout the month of August, in support of Retina UK’s vital work.

• Case study - community
• Written

In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.

• News

Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.

• Case study - research
• Written

We are joined today by Tina Garvey, Chief Execute Officer at Retina UK.

• Podcast
• Audio

Our monthly e-Newsletter featuring the latest updates from Retina UK.

• e-Newsletter
• Audio
• Written

Are you affected by inherited sight loss? We are here to help.

Cataracts occur fairly frequently and at a relatively early age within the Retina UK community of people with inherited retinal conditions. A question that comes up over and over again is whether or not to have cataract surgery.

• Podcast
• Audio

We have created Discover Wellbeing to help people affected by inherited sight loss to develop an awareness of emotional wellbeing and the practical skills to adapt to life’s ups and downs.